Published on British Columbia Drug and Poison Information Centre (BC DPIC) ( http://www.dpic.org)

Home > Drug Product Listings > Trastuzumab emtansine > Printer-friendly PDF

Trastuzumab emtansine

Trade Name: Kadcyla Manufacturer/Distributor: Hoffman-La Roche www.rochecanada.com 1-888-762-4388 Classification: Antineoplastic agent ATC Class: L01XC - other antineoplastic agents Status: active Notice of Compliance (yyyy/mm/dd): 2013/09/11 Date Marketed in Canada (yyyy/mm/dd): 2013/09/27 Presentation: Powder for injection: 20 mg/mL. DIN: 024121365 Comments: Kadcyla? is trastuzumab emtansine. It is a HER2-targeted antibody-drug conjugate for treatment of patients with HER2-positive, metastatic breast cancer who have received both prior treatment with Herceptin? (trastuzumab) and a taxane, separately or in combination. Kadcyla? is a different product from Herceptin?. Keywords: trastuzumab breast neoplasms Access: public Back to: Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database Status: ?

Search Terms: Apply A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4) Date Marketed in Common Trade Generic Name Classification Canada Name(s) (yyyy/mm/dd) Apo- Chlorpropamide Antidiabetic agent 2017/02/01 chlorpropamide Cilazapril Inhibace ACE inhibitor Cladribine Mavenclad Immunosuppressant 2017/11/30 Clindamycin + Biacna Antimicrobial + keratolytic 2010/04 tretinoin Clofedanol Ulone Antitussive Colesevelam Lodalis Bile acid sequestrant 2012/02/06 Crisaborole Eucrisa PDE-4 inhibitor 2018/08/29 ALK Tyrosine Kinase Crizotinib Xalkori Inhibitor Topical immunomodulator Cyclosporine Restasis with anti-inflammatory 2010/10 effects Daclatasvir Daklinza Antiviral agent 2015/09/08 Dacomitinib Vizimpro Tyrosine kinase inhibitor 2019/04/22 Sodium-glucose Dapgliflozin Forxiga contransporter 2 (SGLT2) 2016/02/10 inhibitor Sodium-glucose Dapgliflozin + Xigduo contransporter 2 (SGLT2) 2016/02/08 metformin inhibitor plus metformin Dapsone Aczone Anti-acne therapy 2011/10/21 Antineoplastic agent, Daratumumab Darzalex SC 2020/08/12 monoclonal antibody Darolutamide Nubeqa Anti-androgen 2020/03/24 Darunavir Prezista Antiviral agent 2006 Degarelix Firmagon Antineoplastic agent 2009/11 Denosumab Prolia RANK Ligand inhibitor 2010/08/10 Denosumab Xgeva Bone resorption inhibitor 2011/10/05 Date Marketed in Common Trade Generic Name Classification Canada Name(s) (yyyy/mm/dd) Desogestrel + Apri Oral contraceptive 2009-03-18 ethinyl estradiol Desonide Verdeso Corticosteroid 2011/04/20 Desvenlafaxine Pristiq Antidepressant 2009/03/02 Dexamethasone Ozurdex Corticosteroid 2012/01/19 Dexlansoprazole Dexilant Proton pump inhibitor 2010/07/26 Dexmedetomidine Precedex Alpha-2 adrenergic agonist 2010/02/24 Diclofenac potassium Cambia NSAID 2012/10 Dienogest Visanne Progestin 2011/12/ Difluprednate Durezol Topical corticosteroid 2014/03/12 Apo-digoxin; pms- Digoxin Digoxin; Lanoxin Digoxin Immune Fab Digifab Antidote 2011/12/09 (Ovine) Digoxin Immune Fab Digibind Antidote (Ovine) Misc. central nervous Dimethyl fumarate Tecfidera 2013/04 system agent Dimeticone Nyda Pediculocide 2012/01/17 Dolasetron mesylate Anzemet Antiemetic 2011/05/10 injection Doravirine Pifeltro NNRTI 2018/11/15 « first? previous 1 2 3 4 5 6 7 8 9 ? next ? last »

© 2017 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases. Terms and Conditions Source URL (retrieved on 2021-09-28 01:05): http://www.dpic.org/druglisting/trastuzumab-emtansine